Contineum Therapeutics (CTNM) Liabilities and Shareholders Equity (2023 - 2025)
Historic Liabilities and Shareholders Equity for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $190.8 million.
- Contineum Therapeutics' Liabilities and Shareholders Equity fell 1165.88% to $190.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $784.8 million, marking a year-over-year increase of 1352.55%. This contributed to the annual value of $212.8 million for FY2024, which is 6324.38% up from last year.
- Contineum Therapeutics' Liabilities and Shareholders Equity amounted to $190.8 million in Q3 2025, which was down 1165.88% from $182.9 million recorded in Q2 2025.
- Over the past 5 years, Contineum Therapeutics' Liabilities and Shareholders Equity peaked at $221.4 million during Q2 2024, and registered a low of $123.6 million during Q1 2024.
- In the last 3 years, Contineum Therapeutics' Liabilities and Shareholders Equity had a median value of $194.6 million in 2025 and averaged $184.5 million.
- Per our database at Business Quant, Contineum Therapeutics' Liabilities and Shareholders Equity soared by 6324.38% in 2024 and then plummeted by 1737.8% in 2025.
- Over the past 3 years, Contineum Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $130.4 million in 2023, then surged by 63.24% to $212.8 million in 2024, then decreased by 10.34% to $190.8 million in 2025.
- Its Liabilities and Shareholders Equity stands at $190.8 million for Q3 2025, versus $182.9 million for Q2 2025 and $198.3 million for Q1 2025.